Research programme: allogeneic T-cell therapies - Adaptimmune Therapeutics/Genentech Roche
Alternative Names: Anti-cancer allogeneic T-cell therapies - Adaptimmune/Genentech RocheLatest Information Update: 09 Sep 2021
At a glance
- Originator Adaptimmune; Genentech
- Class Antineoplastics; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 09 Sep 2021 Adaptimmune and Genentech collaborate to co-develop allogeneic T-cell therapies in USA and the UK for cancer
- 09 Sep 2021 Adaptimmune has patent protection for compositions of matter and applications for its T-cell therapies (Adaptimmune website, September 2021)
- 07 Sep 2021 Early research in Cancer in USA, United Kingdom (Parenteral) in September 2021